PL3613733T3 - Nowy krystaliczny stały chlorowodorek 3-fenylo-4-propylo-1-(pirydyn-2-ylo)-1H-pirazol-5-olu - Google Patents

Nowy krystaliczny stały chlorowodorek 3-fenylo-4-propylo-1-(pirydyn-2-ylo)-1H-pirazol-5-olu

Info

Publication number
PL3613733T3
PL3613733T3 PL18788031.5T PL18788031T PL3613733T3 PL 3613733 T3 PL3613733 T3 PL 3613733T3 PL 18788031 T PL18788031 T PL 18788031T PL 3613733 T3 PL3613733 T3 PL 3613733T3
Authority
PL
Poland
Prior art keywords
pyrazol
pyridin
hydrochloride
propyl
phenyl
Prior art date
Application number
PL18788031.5T
Other languages
English (en)
Inventor
Sung Hwan Moon
Soo Jin Lee
Sung Chan Lee
Original Assignee
Aptabio Therapeutics Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aptabio Therapeutics Inc. filed Critical Aptabio Therapeutics Inc.
Publication of PL3613733T3 publication Critical patent/PL3613733T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0031—Rectum, anus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)
PL18788031.5T 2017-04-20 2018-04-20 Nowy krystaliczny stały chlorowodorek 3-fenylo-4-propylo-1-(pirydyn-2-ylo)-1H-pirazol-5-olu PL3613733T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020170050924A KR101856444B1 (ko) 2017-04-20 2017-04-20 3-페닐-4-프로필-1-(피리딘-2-일)-1h-피라졸-5-올 염산염의 신규 결정형 고체 화합물
PCT/KR2018/004604 WO2018194416A1 (ko) 2017-04-20 2018-04-20 3-페닐-4-프로필-1-(피리딘-2-일)-1h-피라졸-5-올 염산염의 신규 결정형 고체 화합물

Publications (1)

Publication Number Publication Date
PL3613733T3 true PL3613733T3 (pl) 2022-09-26

Family

ID=62184173

Family Applications (1)

Application Number Title Priority Date Filing Date
PL18788031.5T PL3613733T3 (pl) 2017-04-20 2018-04-20 Nowy krystaliczny stały chlorowodorek 3-fenylo-4-propylo-1-(pirydyn-2-ylo)-1H-pirazol-5-olu

Country Status (14)

Country Link
US (1) US11174240B2 (pl)
EP (1) EP3613733B1 (pl)
JP (1) JP6982097B2 (pl)
KR (1) KR101856444B1 (pl)
CN (1) CN110678455B (pl)
AU (1) AU2018256259B2 (pl)
CA (1) CA3060046C (pl)
CL (1) CL2019002986A1 (pl)
CO (1) CO2019011547A2 (pl)
ES (1) ES2924798T3 (pl)
MX (1) MX2019012454A (pl)
PL (1) PL3613733T3 (pl)
RU (2) RU2021116820A (pl)
WO (1) WO2018194416A1 (pl)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101840702B1 (ko) * 2017-11-01 2018-03-22 압타바이오 주식회사 간질환 치료제
KR102191180B1 (ko) * 2019-05-31 2020-12-15 삼진제약주식회사 안질환 치료용 조성물
TW202133845A (zh) * 2019-11-21 2021-09-16 韓商三進製藥股份有限公司 用於預防或治療眼部疾病之眼用組合物
KR102308991B1 (ko) * 2020-04-08 2021-10-06 압타바이오 주식회사 조영제 유발 급성 신부전 치료제
MX2022012472A (es) * 2020-04-08 2022-12-15 Aptabio Therapeutics Inc Agente para el tratamiento de lesion renal aguda inducida por medio de contraste.
MX2022012726A (es) * 2020-04-13 2022-11-07 Aptabio Therapeutics Inc Medicamentos para fibrosis pulmonar que contienen derivado de pirazol.
KR102589130B1 (ko) * 2021-03-24 2023-10-13 삼진제약주식회사 N-옥소 피리딘 화합물 발생을 억제하는 안질환 예방 또는 치료용 점안 조성물

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO179282C (no) * 1991-01-18 1996-09-11 Rhone Poulenc Agrochimie Nye 1-(2-pyridyl)pyrazolforbindelser til kontroll av skadeinsekter
SK9742002A3 (en) * 2000-01-07 2003-02-04 Transform Pharmaceuticals Inc High-throughput formation, identification, and analysis of diverse solid-forms
WO2011028043A2 (ko) * 2009-09-02 2011-03-10 이화여자대학교 산학협력단 피라졸 유도체, 이의 제조방법 및 이를 포함하는 골다공증 예방 및 치료용 조성물
US8637674B2 (en) 2009-09-02 2014-01-28 Ewha University-Industry Collaboration Foundation Pyrazole derivatives, preparation method thereof, and composition for prevention and treatment of osteoporosis containing same
KR20120098489A (ko) * 2011-02-28 2012-09-05 이화여자대학교 산학협력단 피라졸 유도체를 포함하는 심혈관 질환 예방 및 치료용 조성물
KR20120098462A (ko) * 2011-02-28 2012-09-05 이화여자대학교 산학협력단 피라졸 유도체, 이의 제조방법 및 이를 포함하는 골다공증 예방 및 치료용 조성물
KR101633957B1 (ko) * 2012-08-27 2016-06-27 이화여자대학교 산학협력단 피라졸 유도체를 포함하는 신장질환 예방 또는 치료용 조성물
TW201603849A (zh) 2014-07-01 2016-02-01 賽諾菲公司 響片配置及其藥物輸送裝置

Also Published As

Publication number Publication date
RU2021116820A (ru) 2021-06-22
RU2754255C2 (ru) 2021-08-31
US20210122726A1 (en) 2021-04-29
RU2019132946A (ru) 2021-04-19
CO2019011547A2 (es) 2020-02-18
ES2924798T3 (es) 2022-10-11
WO2018194416A1 (ko) 2018-10-25
RU2019132946A3 (pl) 2021-04-19
EP3613733B1 (en) 2022-07-20
CA3060046A1 (en) 2018-10-25
EP3613733A4 (en) 2020-11-18
MX2019012454A (es) 2019-12-19
CN110678455A (zh) 2020-01-10
CN110678455B (zh) 2022-08-16
CL2019002986A1 (es) 2020-01-24
EP3613733A1 (en) 2020-02-26
US11174240B2 (en) 2021-11-16
AU2018256259B2 (en) 2020-06-18
JP2020517661A (ja) 2020-06-18
CA3060046C (en) 2021-08-31
JP6982097B2 (ja) 2021-12-17
KR101856444B1 (ko) 2018-05-10
BR112019022002A2 (pt) 2020-05-12
AU2018256259A1 (en) 2019-11-07

Similar Documents

Publication Publication Date Title
IL263429A (en) Crystalline forms of a triazolopyrimidine compound
HUE069702T2 (hu) Heterociklusos vegyület
IL280821A (en) Heterocycline compound
SG10201913200XA (en) Crystalline form of lorlatinib free base
ZA202104402B (en) Heterocyclic compound
HUE066360T2 (hu) Eravaciklin kristályformái
SG11202009356RA (en) Heterocyclic compound
PL3532457T3 (pl) Postacie krystaliczne hydroksynorketaminy
PT3643718T (pt) Composto heterocíclico e seu uso como modulador alostérico positivo do recetor muscarínico colinérgico m1
IL270961A (en) Crystalline form of N-butyldeoxygalactonogirimycin
IL269073A (en) Crystalline forms of obeticholic acid
PL3424930T3 (pl) Kryształ związku wykazującego aktywność hamującą JAK
GB201507036D0 (en) Crystalline enzyme inhibitor compound
IL254115A0 (en) Crystalline forms of a pyrrolpyridine compound
SG11202105355XA (en) Crystalline salts of corydalmine
ZA201907792B (en) Heterocyclic compound
GB201912411D0 (en) Crystalline forms of ivosidenib
IL259981A (en) Crystalline forms of hydrochloride salts of thienopyrimidine compound
IL270937A (en) Crystalline forms of saltalicib
IL277340A (en) The orthocyclic compound
GB201915908D0 (en) Crystalline forms of entrectinib
ZA201907793B (en) Heterocyclic compound
GB201704789D0 (en) Crystalline compounds
HK40025092A (en) Crystalline form of n-butyldeoxygalactonojirimycin
GB201604759D0 (en) Crystalline compounds